CommercialCoverageMedium impact
11.00.13k, Hyperthermic Intraperitoneal Chemotherapy for Select Intra-abdominal and Pelvic Malignancies
Independence Blue Cross·Oncology, General Surgery·Medical Policy
Effective date
Jun 16, 2025
We identified it
Jun 19, 2026
Summary
Independence Blue Cross updated their policy for Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for select intra-abdominal and pelvic cancers. The policy changes include coverage position, medical necessity criteria, billing codes, and general guidelines for this specialized cancer treatment procedure.
Action Required
By June 16, 2025: Billing team should review the updated HIPEC policy at the Independence Blue Cross medical policy portal to understand new coverage criteria, medical necessity requirements, and any coding changes for hyperthermic intraperitoneal chemotherapy procedures. Update prior authorization workflows and documentation requirements as specified in the full policy.